OPEN END-TURBO-OPTIONSSCHEIN - GILEAD SCIENCES | Real-time BOERSE MUENCHEN 02:01:53 2024-07-16 am EDT | ||
| 12.73 EUR | 0.00% |
|
| Current month | +19.98% | ||
| 1 month | +65.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 12.73 | 0.00% |
| 24-07-15 | 12.73 | +3.50% |
| 24-07-12 | 12.3 | +3.36% |
| 24-07-11 | 11.9 | +10.59% |
| 24-07-10 | 10.76 | +6.96% |
Real-time BOERSE MUENCHEN
Last update July 16, 2024 at 02:01 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | TT4Q9H |
| ISIN | DE000TT4Q9H8 |
| Date issued | 2020-11-11 |
| Strike | 57.17 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 5.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.72 € |
|---|---|
| Lowest since issue | 4 € |
| Spread | 0.5 € |
| Spread % | 3.80% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.81
USD
Average target price
83.08
USD
Spread / Average Target
+17.33%
- Stock Market
- Certificates
- Certificat
